Commercialization and Regulation of Regenerative Medicine Products: Promises, Advances and Challenges Publisher Pubmed



Beheshtizadeh N^{1, 9} ; Gharibshahian M^{2, 9} ; Pazhouhnia Z^{1, 9} ; Rostami M^{3, 7} ; Zangi AR⁴ ; Maleki R⁵ ; Azar HK⁶ ; Zalouli V⁹ ; Rajavand H⁹ ; Farzin A^{8, 9} ; Lotfibakhshaiesh N^{1, 9} ; Sefat F^{10, 11} ; Azami M^{1, 9} ; Webster TJ^{12, 13, 14} Show All Authors Show Affiliations
Source: Biomedicine and Pharmacotherapy Published:2022

Abstract

The ultimate goal of regenerative medicine is to repair, regenerate, or reconstruct functional loss in failed tissues and/or organs. Although regenerative medicine is a relatively new field, multiple diverse research groups are helping regenerative medicine reach its objectives. All endeavors in this field go through in silico, in vitro, in vivo, and clinical trials which are prerequisites to translating such approaches from the bench to the bedside. However, despite such promise, there are only a few regenerative medicine approaches that have actually entered commercialization due to extensive demands for the inclusion of multiple rules, principles, and finances, to reach the market. This review covers the commercialization of regenerative medicine, including its progress (or lack thereof), processes, regulatory concerns, and immunological considerations to name just a few key areas. Also, commercially available engineered tissues, including allografts, synthetic substitutes, and 3D bioprinting inks, along with commercially available cell and gene therapeutic products, are reviewed. Clinical applications and future perspectives are stated with a clear road map for improving the regenerative medicine field. © 2022 The Authors